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Background: Shigellosis is a common cause of morbidity, especially in the very young and old, in developing countries.  The disease is 
treated with antibiotics. Surveillance of antimicrobial resistance trends is essential owing to the global emergence of antimicrobial resistance. 
Methodology: The study involved 1,573 isolates of Shigella species (1996-2007) that were analyzed for trends in antimicrobial resistance. 
Results: The majority of the specimens (1046; 66.5%) were from the pediatric population, and of these 887 (84.8%) were under 5 years of 
age (p = 0.001). S. flexineri was the most frequent species (54.5%) isolated. Isolation of S. sonnei increased from 15.4 % (1996) to 39% 
(2007) (p = 0.001). Although none of the isolates was found sensitive to all the antibiotics tested, 58% (n =9 07) were resistant to ampicillin 
and 85% (n = 1,338) were resistant to trimethoprim-sulfamethoxazole (TMP-SMX). Out of a total of 198 (12.6%) nalidixic acid resistant 
isolates, 6 (3.0%) were also resistant to ofloxacin. Overall 1.7 % of isolates were resistant to ofloxacin, 2.4% to ceftriaxone and 2.3% were 
resistant to combination of ampicillin, nalidixic acid and TMP-SMX. 
Conclusion: Ofloxacin is still an effective drug for treatment of acute shigellosis in Pakistan. Emergence of resistance to ceftriaxone in 
Shigella may have grave implications in treatment of severe shigellosis in very young patients. 
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Introduction 
Infection by any of the Shigella species, namely 
S. dysenteriae, S. flexneri, S. boydii and S. sonnei, 
may lead to shigellosis. Global burden of shigellosis 
is estimated to be approximately 164.7 million cases 
annually with approximately 163.2 million cases 
from developing countries [1]. Prompt treatment with 
appropriate antimicrobial agents not only shortens the 
duration and severity of the illness but also reduces 
microbial carriage and thus spread of infection in the 
community. 
Emergence of antimicrobial resistance has 
complicated the empirical therapy for treatment of 
shigellosis. Ampicillin was replaced by TMP-SMX 
and nalidixic acid as preferred drugs owing to 
emergence of resistance in the early 1970s [2]. 
Resistance to TMP-SMX made prominence in the 
1980s with reports of resistant isolates from many 
countries [3]. More recently, strains resistant to 
nalidixic acid and those with high Minimum 
Inhibitory Concentration (MIC) for fluoroquinolone 
have been reported [3,4,5], alerting clinicians to 
probable treatment failure. Reports of ceftriaxone 
resistance in Shigella spp. from various countries 
owing to ESBL production is another major concern 
[5,6]. 
Developing countries such as Pakistan lack 
infrastructure to monitor anti-microbial resistance at 
the national level; therefore, guidelines for 
antimicrobial treatment are limited. Over-the-counter 
drug availability and self-medication instigates rapid 
selection and emergence of resistant strains in the 
community.  
This study was conducted to analyze the 
antibiotic resistance trend in the Shigella species at 
our center to guide clinicians regarding the treatment 
options of shigellosis in Pakistan. Since Pakistan is 
one of the most commonly reported regions of 
imported cases of shigellosis in the developed world, 
the results of our study would be of international 
interest. To the best of our knowledge, this is the 
largest dataset of Shigella isolates reported from 
Pakistan. 
 
Materials and methods 
Location and sampling 






















Aga Khan University Hospital (AKUH) is a 550-
bed tertiary care centre located in Karachi, Pakistan. 
The clinical microbiology laboratory receives 
samples across the country via its satellite units in 
more that 50 cities and towns. We analyzed all stool 
samples submitted for bacterial culture in the 
laboratory between the years 1996 and 2007. Stool 
samples were processed according to the standard 
methodology. Colonies morphologically suggestive 
of Shigella species were identified by conventional 
biochemical reactions (urea, citrate, triple sugar iron, 
indole, motility) and slide agglutination tests using 
antisera from Denka Seiken Co. Ltd, Japan. Non-
serotypable isolates were further checked by API 20 
E (Bio Murex, France). Antibiotics susceptibility was 
performed by Kirby Bauer disk diffusion method, 
against Ampicillin (10ug), Ceftriaxone (30ug), 
Cotrimoxazole (TMP-SMX) (25ug), Nalidixic acid 
(30ug) and Ofloxacin (5ug).  MIC of selected agents 
was performed by E-Test (AB Biodisk, Solna, 
Sweden) according to the manufacturer’s 
recommendations. ESBL production was detected by 
combined disc method (ceftriaxone alone and 
ceftriaxone-clavulanic acid). Escherichia coli ATCC 
25922 and Klebsiella pneumoniae ATCC 700603 
were used as the quality control strains. 
 
Definitions 
The pediatric population was defined as children 
younger than 15 years of age. The antibiotic 
resistance pattern was defined as follows: Pan 
sensitive Shigella (PSS) Shigella isolates sensitive to 
all the antibiotics tested. The multi-drug resistant 



















resistant to ampicillin, TMP-SMX, and nalidixic acid. 
MDR isolates with additional resistance to ofloxacin 
and /or ceftriaxone were defined as extremely 
resistant strains (XDR). 
 
Statistical analysis   
Analysis was performed using SPSS version 15.0 
for Windows (Statistical Package for Social Sciences, 
Chicago IL, USA). Mean median, standard deviations 
(SD) and interquartile ranges (IQR) were calculated 
for continuous variables. Categorization of 
independent continuous variables and categorical 
variables were calculated in a statistically meaningful 
way. 
Descriptive analysis of age, gender, location and 
other characteristics were computed separately for 
our study population. The mean and standard 
deviation was computed for continuous variable by 
independent t-test. Proportions for categorical 
variables were calculated and compared by chi-square 
test.  
A detailed stratum specific analysis on 
ceftriaxone resistance was done among different age 




Age and demographics 
During the study period (1996-2007) a total of 
1,573 samples were positive for Shigella species. The 
majority (1046; 66.5%) were from the pediatric 
population, and of these 887 (84.8%) were under 5 
years of age (p = 0.001).  
 
Figure 1. Frequency of different species of Shigella isolates detected at clinical laboratory of Aga 
Khan University Hospital Karachi (1996-2007). 







Monthly distribution  
Month-wise distribution of Shigella isolation was 
analyzed during the study period. Shigella isolation 
occurred throughout the year, with significant 
increases noted in July and August, corresponding 
with the monsoon season. 
 
Microbiology 
S. flexneri was the most frequent species (54.5%) 
identified in both the adult and pediatric age groups. 
Isolation of S. sonnei progressively increased from 
15.4 % (n =4) in 1996 to 33.3% (n = 18) in 1999 and 
peaked in 2004 to 44.1% (n = 45; p = 0.001). Peak 
isolation of S. sonnei corresponded with a relative fall 
of S. flexneri in that period (Fig.1). Percent isolation 
of S. boydii isolates increased from 0% in 1996 to a 
peak of 10.1% in 2003 (n = 36). S. dysentriae 
isolation decreased from 7.7% in 1996 to 0% in 2005 
(p = 0.001). 
 
Antibiotic resistance  
During the study period resistance to ampicillin 
and cotrimoxazole remained high with fluctuations. 
Significant increases in resistance were noted for 
chloramphenicol, nalidixic acid, and ofloxacin. 
Ceftriaxone resistance emerged in 2001 and increased 
to 8% in year 2007. None of the isolates was found to 
be PSS i.e. sensitive to all the antibiotics tested. A 
large proportion of isolates was resistant to ampicillin 
i.e.907 (58%) and TMP-SMX i.e.1338 (85%); 797 
(50.7%) of isolates had co-resistance to both drugs 
(Table 1). 
Ampicillin resistance was noticed in all four 
species, the highest being in S. flexneri (n = 763; 
84.1%), whereas 4.4% (n = 40) S. sonnei isolates 





was more common among S. flexneri isolates than 
that of S. sonnei (54.6% vs. 33.0; p = 0.001). 
Resistance to chloramphenicol emerged in 1998 
(2.3%; n = 3), and increased to 37.6% (n = 38) in 
2007 (p = 0.001). Chloramphenicol resistance was 
more frequent in S. flexneri (86.2%) followed by S. 
dysentriae and S .boydii (6.3% and 4.7% 
respectively). 
Shigella isolates resistant to nalidixic acid were 
first noted in 1997 with the highest number of 
resistant isolates 44 (23%) in 2005. Overall resistance 
to nalidixic acid was common in S. sonnei (n = 116; 
28.5%) and rare in S. flexneri (n = 25; 3.2%; p = 
0.001). Resistance to ofloxacin emerged in 2001 and 
increased to 10.9% in 2007 (n = 11; p = 0.001.  
The most alarming finding of this study was 
detection of resistance to ceftriaxone that emerged in 
2001: 65.8% (n = 25) of ceftriaxone resistant isolates 
were from patients between two and five years of age. 
Resistance was mainly seen in S. flexneri (n = 27; 
71.1%) followed by S. sonnei (n = 10; 26.3%). The 
highest number of ceftriaxone resistant isolates was 
detected in 2005, n = 16 (8.2%). Prior to 2005 
ceftriaxone resistance was tested by disc diffusion 
method; however, from 2005 onwards (due to 
heightened alert) all resistant isolates were 
reconfirmed by MIC using E-test (MIC values > 
32mg/dl). Ceftriaxone resistant isolates were also 
resistant to other first line drugs; however, none of 
these isolates was found resistant to ofloxacin. All the 
ceftriaxone resistant Shigella spp. were ESBL 
producers. 
Thirty-six (2.3%) of the total isolates were 
resistant to a combination of ampicillin, nalidixic acid 
and TMP-SMX (MDR). None of the MDR isolates 
showed additional resistance to ofloxacin and /or 
ceftriaxone (XDR = 0). 
AB 
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Total P-
value n=26 n=91 n=131 n=54 n=41 n=89 n=274 n=355 n=102 n=194 n=115 n=101 n=1573 
SXT 69.2 78 90.1 83.3 80.5 84.3 83.2 92.1 83.3 87.1 73.9 83.2 85.1 <0.001 
AMP 73.1 63.7 57.3 59.3 58.5 51.7 60.6 64.5 37.3 58.8 51.3 46.5 57.7 0.002 
C 0 0 2.3 11.1 29.3 33.7 34.3 47.3 27.5 37.1 37.4 37.6 31.4 <0.001 
NA 0 1.1 6.1 7.4 7.3 2.2 4.7 9.9 19.6 23.0 22.6 41.6 12.6 <0.001 
OFX 0 0 0 0 0 1.1 0.4 1.1 2 1 4.3 10.9 1.7 <0.001 
CRO 0 0 0 0 0 2.2 1.1 0.8 4 8.2 2 8 2.4 <0.001 
PSS 0 0 0 0 0 0 0 0 0 0 0 0 0 - 
MDR 0 1 4 7 2 1 3 1 1 3 1 5 2.3   
XDR 0 0 0 0 0 0 0 0 0 0 0 0 0 - 
Table 1. Percent resistance of Shigella species over period of twelve years isolated at Clinical Laboratory of Aga Khan University 








AB: Antibiotic; SXT: septran; AMP: ampicillin; C: chloramphenicol; NA: nalidixic acid; OFX: ofloxacin; CRO Ceftriaxone, PSS: Pan Sensitive Shigella; MDR: resistant to three first-line drugs; 
XDR: MDR + resistance to ofloxacin and/ or ceftriaxone   
 




Discussion   
Shigellosis is primarily a disease of children and 
young adults. The majority of shigellosis cases in our 
population was seen in patients younger than five 
years. Transmission of Shigella commonly occurs by 
person-to-person contact and through food, water and 
fomites [7]. Flies play important role in the spread of 
Shigella [8]; therefore, in endemic countries, 
shigellosis occurs throughout the year peaking during 
the hot humid and rainy season [9]. Results of our 
study also reflect this finding with an increase of 
cases noted in monsoons.  
S. flexneri is reported as the most frequent species 
from Asia [5,10,11]. Although our findings are 
consistent with this data, our study has revealed an 
epidemiological shift with progressive increases in S. 
sonnei and S. boydii during the study period. 
Changing epidemiology of shigellosis has been 
reported from other countries. S. flexneri was the 
most frequent serotype in the United States of 
America in the early 1960s, but that was replaced by 
S. sonnei during 1964-68 [12]. A recent report from 
Iran has indicated a shift from S. flexneri to S. sonnei 
as the most frequently isolated serotype [13]. 
Compared with previous reports, Lorenz et al. has 
reported increase in number of S. boydii in 
Bangladesh [11]. Follow-up studies are required to 
observe the persistence of this finding in our setup.  
Antibiotic resistance among Shigella species is 
increasingly being reported from developed as well as 
developing countries [4,5]. None of the isolates over 
the period of twelve years in our study was pan 
sensitive. The proportion of isolates resistant to 
ampicillin, TMP-SMX, and both increased 
substantially over the study period. These agents are 
therefore no longer appropriate for the empirical 
treatment in our population.  
The role of nalidixic acid as an empirical drug for 
treatment of acute shigellosis in young children is 
also being compromised in our population, as 12.6% 
of Shigella isolates were resistant to nalidixic acid 
and of these 3.8% were also resistant to ofloxacin. 
Our findings are consistent with data from other 
developing as well as developed countries [3,4, 5]. In 
addition, nalidixic acid resistant isolates with high 
MIC for higher generation quinolones have also been 
reported from the United Kingdom [3]. 
Overall resistance to ofloxacin in our study 
isolates was low (1.7%), suggesting that 
fluoroquinolone is still an effective drug for treatment 
of acute shigellosis in our population; however, 
treatment failures due to resistant strains can occur. It 
is therefore important that Shigella isolates be tested 
for resistance before treatment is commenced by 
nalidixic acid and higher generation 
fluoroquinolones. 
Resistance to ceftriaxone has been previously 
reported from Asian countries [10]. A single case 
report of ceftriaxone resistant S. flexneri was reported 
from our center in early 2005 [14]; subsequently, the 
clinical laboratory was put on high alert and all 
isolates detected (on disc diffusion method) thereafter 
were confirmed by MICs. Third-generation 
cephalosporins are mainstays in the treatment of 
severe forms of diarrhoeal infections, especially in 
very young children in whom the use of 
fluoroquinolone is restricted. Resistance to this group 
of antibiotics is alarming, especially in the backdrop 
of plasmid mediated extended spectrum beta- 
lactamase (ESBL) producing Klebsiella and other 
Enterobacteriaceae which are increasingly being 
isolated at our center. All ceftriaxone resistant 
isolates were ESBL producers and further studies to 
identify the type of ESBL in these strains are 
underway at our center.    
Our study has some limitations. First, it is a 
retrospective analysis of laboratory data and findings 
cannot be generalized to the entire population. The 
results of our study may be an overestimation of 
resistance among Shigella isolates due to sampling 
bias. Secondly, most of the antibiotic resistance was 
detected by disc diffusion method and MIC 
breakpoints for nalidixic acid and ofloxacin could not 
be determined. Despite these limitations, the findings 
of our study have identified changing epidemiology 
and emerging resistance in our Shigella isolates. 
These findings will certainly guide clinicians (local 
and international) to the options of treatment of 
shigellosis in patients within or those traveling from 
Pakistan.     
In conclusion, our study has revealed an 
epidemiological shift with progressive increase in S. 
sonnei and S. boydii in our population. Antibiotic 
resistance in Shigella species at our center has 
increased at an alarming level. Substantial increase in 
ampicillin and TMP-SMX resistance precludes use of 
these agents for empirical treatment in our 
population. Fluoroquinolone is an option; however, it 
is important that Shigella isolates be tested for 
resistance before treatment is commenced by 
nalidixic acid and higher fluoroquinolones. 
Emergence of resistance to ceftriaxone in Shigella 
strains is a call for concern and an alarm for health 
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